Cash runway extends only into Q1 2027, requiring additional financing within months. Delisting risk adds urgency. Initial TakeAim CLL data in December 2026 is the next binary catalyst but early-stage and unlikely to change the cash trajectory.
Drug in focus
CRIS drug pipeline →emavusertib
◆ Mixed Named in this press release- Impact
- Phase
- Phase 2 (registrational-intent in PCNSL)
- Time to market
- Uncertain; the registrational PCNSL study is still enrolling with full enrollment targeted within 12-18 months from March 2026. If data are positive and an NDA follows, potential approval would be at least 2-3 years out, assuming sufficient capital to complete the trials.
- Next catalyst
- None dated
What to watchThe next major catalyst is a topline data readout from the registrational TakeAim Lymphoma study in PCNSL, which management targeted to fully enroll within 12-18 months from March 2026 (so late 2027 at the earliest). No specific readout date has been announced. In the near term, watch for the shareholder vote on the proposed reverse stock split, which the company needs to maintain Nasdaq listing, and for any further financing rounds given the cash burn (Q3 2026 net loss of $8.12M).
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $0.4450entry
- T+1 · 20h ago −2.07%α −0.16% · $0.4358
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Curis reported Q3 2026 net loss of $8.1M ($1.94 per share) with zero revenue after selling Erivedge royalties in Q4 2025. The company has $5.0M cash plus $7.5M from an October private placement, funding operations only into Q1 2027, and faces Nasdaq delisting risk. Clinical progress in emavusertib studies is early-stage with no near-term revenue catalyst.
Key Financial Metrics
Key Facts
- Q3 2026 net loss $8.1M ($1.94 per share) vs $7.7M ($9.86) in Q3 2025
- Zero revenue in Q3 2026 after Erivedge royalty sale in Q4 2025
- Cash and equivalents $5.0M as of Sep 30, 2026; plus $7.5M from Oct 2026 private placement
- Cash runway only into Q1 2027
- Nasdaq delisting determination received Nov 2, 2026; hearing requested but no assurance
- 12 patients enrolled in TakeAim CLL study; initial data expected Dec 2026
- R&D expenses $5.6M in Q3 2026 vs $6.4M in Q3 2025
- 4.1M shares outstanding as of Sep 30, 2026
Financial Impact
Net loss $8.1M in Q3 2026; cash burn rate ~$2.7M/month; cash runway into Q1 2027 only
Risk Factors
- Nasdaq delisting likely given reverse split already used and discretionary panel monitor
- Cash runway only into Q1 2027; substantial additional capital needed
- Zero revenue; no near-term commercialization prospects
- Early-stage clinical data may not support regulatory approval
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302938385 |
Track record
18 reports on CRIS
6 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +82.45% at T+60 after the May 22, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $0.4200 Now $0.4400 +4.76% settles Nov 17
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $0.6000 Now $0.4400 −26.67% settles Nov 17
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $0.5010 Now $0.4400 −12.18% settles Nov 17
- Nov 13, 20263d ago S-3 Bearish 7/10 Entry $0.6000 Now $0.4400 +26.67% settles Nov 17
- Nov 13, 20263d ago 8-K Neutral 4/10 Entry $0.4450 Now $0.4400 −1.12% settles Nov 17
- Nov 12, 20264d ago Press Release Bearish 6/10 Viewing Entry $0.4450 to $0.4358 Now $0.4400 +1.12% ▲ +2.07% +0.16% vs SPY
- Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $0.6530 to $0.5915 Now $0.4400 −32.62% ▼ −9.42% −10.74% vs SPY
- Nov 6, 202610d ago 8-K Bearish 7/10 Entry $0.6976 to $0.6530 Now $0.4400 +36.93% ▲ +6.39% +6.03% vs SPY
- Nov 2, 202614d ago DEF 14A Neutral 4/10 Entry $0.6610 to $0.7139 Now $0.4400 −33.43% ▲ +8.00% +7.70% vs SPY
- Oct 19, 202628d ago 8-K Bearish 6/10 Entry $0.3996 to $0.3920 Now $0.4400 −10.11% ▲ +1.90% +2.43% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers